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Background: Four electronic devices for self-measurement of brachial blood pressure (BP): 
the Omron M1 Plus, the Omron M6 Comfort, the Spengler KP7500 D, and the Microlife BP 
A100 Plus, were evaluated in four separate studies according to the International Protocol of 
the European Society of Hypertension (ESH). 
Design: The International Validation Protocol is divided into 2 phases: the ﬁ  rst phase is per-
formed on 15 selected subjects (45 pairs of BP measurements); if the device passes this phase, 
18 supplementary subjects are included (54 pairs of BP measurements) making a total number 
of 33 subjects (99 pairs of BP measurements) on which the ﬁ  nal validation is performed.
Methods: The same methodology recommended by the ESH protocol was applied for the 
4 studies. In each study and for each subject, 4 BP measurements were performed simultaneously 
by 2 trained observers using mercury sphygmomanometers alternately with 3 measurements by 
the tested device. The difference between the BP value given by the device and that obtained by 
the two observers (mean of the two observers) was calculated for each measure. The 99 pairs of 
BP differences were classiﬁ  ed into 3 categories (≤5, ≤10, ≤15 mmHg). The number of differ-
ences in each category was compared with the number required by the International Protocol. 
An individual analysis was then done to determine for each subject the number of comparisons 
≤5 mmHg. At least 22 of the 33 subjects should have 2 of their 3 comparisons ≤5 mmHg.
Results: All 4 tested devices passed the ﬁ  rst and the second phase of the validation process. 
The average differences between the device and mercury sphygmomanometer readings 
were –1.4 ± 5.5 and –0.4 ± 4.8 mmHg for SBP and DBP respectively for the Omron M1 Plus 
device, –2.1 ± 7.4 and 0.1 ± 4.9 mmHg for SBP and DBP respectively for the Omron M6 Com-
fort device, –1.4 ± 8.6 and –0.1 ± 3.5 mmHg for SBP and DBP respectively for the Spengler 
KP7500 D device, and 1.6 ± 4.2 mmHg and 0.54 ± 2.8 mmHg for SBP and DBP respectively 
for the Microlife BP A100 Plus device. For all devices, readings differing by less than 5, 10, 
and 15 mmHg for SBP and DBP values fulﬁ  ll the recommendation criteria of the International 
Protocol as well as the individual analysis.
Conclusions: Omron M1 Plus (HEM-4011C-E), Omron M6 Comfort (HEM 7000-E), Spengler 
KP7500 D, and Microlife BP A100 Plus devices fulﬁ  lled the validation recommendations of 
the International Protocol.
Keywords: Omron M1 Plus (HEM-4011C-E), Omron M6 Comfort (HEM-7000-E), Spengler 
KP7500 D and Microlife BP A100 Plus, validation, International Protocol, self-blood pressure 
measurement
Introduction
Advantages of blood pressure (BP) self-measurement have been well documented 
(Pickering et al 1996; White 1998; O’Brien et al 2005). Indeed, self-BP measurement Vascular Health and Risk Management 2007:3(4) 390
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(sBPm) not only provides valuable information for hyperten-
sion diagnosis but also on BP control of the treated patient, 
and it improves patient’s compliance with antihypertensive 
therapy (Haynes et al 1976). Therefore, it is appropriate to 
encourage the widespread use of self-recorded BP as an 
important adjunct to the clinical care of some patients with 
hypertension (Thijs et al 1998; Asmar et al 2000). Clinical 
indications of sBPm have been recently highlighted in several 
international scientiﬁ  c society recommendations (Asmar et al 
2000; O’Brien et al 2005). Obviously, BP self-measurement 
is only practicable if the devices are accurate, user-friendly, 
and relatively inexpensive. Particular attention must be paid 
to ensure the accuracy of the used devices (O’Brien et al 
1993a). Ideally, recommended devices should have been sub-
mitted to independent clinical validation procedures. During 
recent years, various automated devices for self-measurement 
of BP have been fabricated, but only some have been vali-
dated (O’Brien et al 1993a, 1996; Foster et al 1994; Modesti 
et al 1996; Cordoba et al 1997; Bortolotto et al 1999; Naschitz 
et al 2000; Mattu et al 2001; White et al 2001; El Assaad et al 
2002; Cuckson et al 2002; Golara et al 2002; Ploin et al 2002; 
El Assaad et al 2003; Alpert et al 2004; Nolly et al 2004; 
Verdecchia et al 2004; Stergiou et al 2006; Topouchian et al 
2006) according to recognized protocols speciﬁ  cally designed 
for this purpose, such as the British Hypertension Society 
(BHS) protocol (O’Brien et al 1990, 1993b), the Association 
for the Advancement of Medical Instrumentation (AAMI) 
protocol (AAMI 1987, 1993) and the most recent Internation-
al Protocol (O’Brien et al 2002) published by the European 
Society of Hypertension (ESH). In this study, 4 devices for 
self-measurement of BP were validated according to the ESH 
protocol in 4 separate studies (O’Brien et al 2002). 
Methods
Devices
Omron M1 plus (HEM-4011C-E)
The Omron M1 Plus device records brachial BP oscillo-
metrically with a BP measurement range of 0–299 mmHg 
and heart rate range of 40–180 beats/min. Systolic blood 
pressure (SBP), diastolic blood pressure (DBP), and heart 
rate are displayed on a liquid crystal digital (LCD) read-
out. Inﬂ  ation is manual by pumping the inﬂ  ation bulb. 
Measurement starts automatically after having stopped 
inﬂ  ating the arm cuff. Deﬂ  ation is made by pressing the 
air release button to release the air in the arm cuff; this is 
an automatic pressure release valve. Standard cuff type 
adult for an arm circumferences ranging from 220 to 320 
mm is provided. 
Omron M6 comfort (HEM-7000-E)
The Omron M6 Comfort (HEM 7000-E) device records bra-
chial BP oscillometrically with a BP measurement range of 
0–299 mmHg and heart rate range of 40–180 beats/min. SBP, 
DBP, and heart rate are displayed on an LCD read-out. The 
inﬂ  ation is performed using a fuzzy-logic electric pumping 
system and the deﬂ  ation by an automatic pressure release 
valve. Standard cuff type adult for an arm circumference 
ranging from 220 to 420 mm is provided, which ﬁ  ts both 
standard and large arm circumferences (cuff dimensions: 
152 × 600 mm; weight: 240 g).
Spengler KP7500D
The Spengler KP7500D device records brachial BP oscillo-
metrically with a BP measurement range of 20–300 mmHg 
and heart rate range of 40–200 beats/min. SBP, DBP, and 
heart rate are displayed on an LCD read-out. Inﬂ  ation is 
automatic by a micro rolling pump. Measurement starts 
automatically after having pressed and released the power 
button. Deﬂ  ation is automatic by an automatic pressure 
release valve to release the air in the arm cuff. Standard 
adult cuff type for an arm circumference ranging from 220 
to 320 mm is provided.
Microlife BP A100 plus
The Microlife BP A100 Plus device records brachial 
BP oscillometrically with a BP measurement range of 
30–280 mmHg and heart rate range of 40–200 beats/min. SBP, 
DBP, and heart rate are displayed on an LCD read-out. Meas-
urement starts automatically; deﬂ  ation is also automatic by a 
constant air release solenoid valve. Standard adult cuff type for 
an arm circumference ranging from 220 to 320 mm is provided. 
Two other cuffs, small (arm circumference 170–220 mm), and 
extra large cuffs (320–420 mm) are optional.
Device validation
Each device was validated separately in speciﬁ  c populations 
and at different times. Therefore, each patient participated in 
only one study device validation. The devices were validated 
according to the ESH protocol. For each study, the manufac-
turer was asked to loan 2 or 3 devices with 2 different size 
cuffs (medium and large).
Factors affecting accuracy of measurements were 
described by the manufacturers according to the require-
ments of the International Protocol and were taken into 
consideration during the validation procedure.
The validation team consisted of 3 persons experienced 
in BP measurement who also had received training based Vascular Health and Risk Management 2007:3(4) 391
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on a CD-ROM (Groupe d’Evaluation et de Mesure de la 
Société Française d’Hypertension Artérielle 1998) speciﬁ  cally 
developed by the French Society of Hypertension for the 
certiﬁ  cation of observers involved in clinical studies. Two 
of the three observers simultaneously measured BP using a 
standard mercury sphygmomanometer, the components of 
which had been carefully checked before the study, and the 
third observer was the supervisor who checked the values 
obtained by the two observers and measured the BP by the 
tested device. 
Analysis according to the International Protocol consisted 
of 2 phases. In the ﬁ  rst phase, 15 subjects (45 BP measure-
ments) were recruited; devices passing this primary phase 
proceeded to the second phase, for which a further 18 subjects 
(54 BP measurements) were recruited. All the devices were 
validated at the same center, by the same observers but at 
different times and in different populations.
Subject selection
For each study, selection of subjects was done accord-
ing to the recommendations of the International Protocol 
(Table 1). Four different populations were used in these 4 
validation procedures. Arm circumferences were measured 
in each patient to ensure the use of an adequate cuff size; 
arm circumferences were distributed by chance according 
to the ESH protocol. In order to fulﬁ  ll the BP criteria ranges 
and to optimize recruitment, it is recommended that subjects 
for the high diastolic and low systolic groups should be 
recruited ﬁ  rst, then those with high systolic and low diastolic, 
and ﬁ  nally the remaining gaps should be ﬁ  lled. Thirty-three 
subjects with both SBP and DBP measurements correspond-
ing to the requested BP ranges were selected to validate each 
of the four devices.
For the primary phase, 5 of the 15 subjects should have 
an SBP in each of the ranges. Similarly, 5 of the 15 subjects 
should have a DBP in each of the ranges. For the second 
phase, 11 of the 33 subjects (including the ﬁ  rst 15 subjects) 
should have SBP and DBP in each of the ranges. There are 
3 ranges for SBP and 3 for DBP, with 11 subjects in each 
range to provide 99 pairs of measurements. Final analysis is 
performed on the 99 paired measurements.
Procedure
BP measurements by the observers
The subjects were seated in a quiet room and BP measure-
ments started after a 10-minute rest period. Arm circumference 
was measured and brachial BP cuff size was adapted to the 
circumference. All measurements were made on the left arm 
at the heart level. BP was measured simultaneously (Y tube) 
with 2 calibrated mercury sphygmomanometers by the two 
observers alternately with the device undergoing validation. 
The observers were blinded to each other’s readings.
Measurements were carried out in the following sequence 
for all 4 validation procedures:
BPA Entry BP, observers 1 and 2 each with independent 
mercury standard sphygmomanometer. The mean values 
were used to categorize the subject into a low, medium, or 
high range separately for SBP and DBP (Table 1).
BPB Device detection BP, observer 3. This BP was mea-
sured to allow the tested device to determine the BP character-
istics of the subject and was not included in the analysis.
BP1 Observers 1 and 2 with the mercury standard.
BP2 Supervisor with the tested device.
BP3 Observers 1 and 2 with the mercury standard.
BP4 Supervisor with the tested device.
BP5 Observers 1 and 2 with the mercury standard.
BP6 Supervisor with the tested device.
BP7 Observers 1 and 2 with the mercury standard.
Accuracy criteria
The concept of the International Protocol is to classify the 
differences between the device tested and control measure-
ments according to whether these differences lie within 
5, 10, or 15 mmHg. Differences are always calculated by 
subtracting the tested observer measurement from the device 
measurement. Differences were classiﬁ  ed separately in this 
way for both SBP and DBP. 
Subject measurements
For assessment of accuracy, only measurements BP1 to BP7 
were used. The mean of each pair of observer measurements 
was calculated; this was denoted as observer measurement 
BP1, BP3, BP5, or BP7. Each device measurement was 
ﬂ  anked by two of these observer measurements, and one 
of these was selected as the comparative measurement as 
follows: 
1- The differences between BP2-BP1, BP2-BP3, BP4-BP3, 
BP4-BP5, BP6-BP5, and BP6-BP7 were calculated.
Table 1 BP ranges for entry BP
  SBP (mmHg)  DBP (mmHg)
Low 90–129  40–79
Medium 130–160  80–100
High 161–180  101–130
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure.Vascular Health and Risk Management 2007:3(4) 392
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2- The absolute values of the differences were calculated. 
3- These were paired according to the device reading. 
4- If the values in a pair were unequal, the observer measure-
ment corresponding to the smaller difference was used. 
5- If the values in a pair were equal, the ﬁ  rst of the 2 observer 
measurements was used. 
When this had been completed, there were 3 device 
readings for SBP and 3 for DBP for each subject. Each of 
these 6 readings had a single corresponding observer mea-
surement, a difference between the two and a band for that 
difference categorized as follows: (0–5 mmHg, 6–10 mmHg, 
11–15 mmHg, >15 mmHg).
Assessment
After all BP ranges have been ﬁ  lled (Table 1), there were 
45 sets of measurements for both SBP and DBP for the ﬁ  rst 
phase (15 subjects) and 99 sets for the second phase (33 
subjects). 
The number of differences in each zone was calculated 
and compared to the number required by the International 
Protocol and a continue/fail grade for ﬁ  rst phase and pass/fail 
grade for second phase (phase 2.1) was determined. Also 
for the second phase, the number of measurements falling 
within 5 mmHg was determined for each of the 33 subjects 
and a pass/fail recommendation was determined according to 
the protocol (phase 2.2). For this phase at least 22 of the 33 
subjects should have at least 2 of their 3 comparisons lying 
within 5 mmHg. And at most 3 of the 33 subjects can have 
all three of their comparison over 5 mmHg apart. To pass the 
validation and to be recommended for clinical use, a device 
must pass both phase 2.1 and phase 2.2. If it does not, it fails 
and is not recommended for clinical use.
Results
Different populations were used in each of the validation pro-
cedures. The number of subjects screened for each device’s 
study was: 43 pre-included subjects for the Omron M1 Plus, 
52 for the Omron M6 Comfort, 46 for the Spengler KP7500 
D, and 47 for the Microlife BP A100 Plus.
Omron M1 plus (HEM-4011C-E)
In the Omron M1 Plus study, mean age of the 33 subjects 
included was 58 ± 13 (21 men and 12 women), the arm 
circumference was 28 ± 4 (range: 19–38), and 26 standard 
cuffs, 6 large cuffs, and 1 small cuff were used (Table 2). 
The BP difference between the two observers was 0.95 ± 1.4 
mmHg and 0.08 ± 0.84 mmHg for SBP and DBP respectively. 
The mean values of 99 measurements for SBP and DBP were 
respectively 136.5 ± 20.9/89.6 ± 16.4 mmHg with the Omron 
M1 Plus (HEM-4011C-E) device and 137.9 ± 22.1/90 ± 16 
mmHg with the standard mercury sphygmomanometer. The 
mean and standard deviation of the difference between the 
device and the observers were –1.4 ± 5.5 and –0.4 ± 4.8 
mmHg for SBP and DBP respectively.
In total, 45 measurements (3 measurements × 15 subjects) 
were available for analysis in the ﬁ  rst phase of the valida-
tion process, and 99 (3 measurements × 33 subjects) in the 
second phase. The number of measurements differing from 
the mercury sphygmomanometer standard by 5, 10, and 15 
mmHg or less are shown in Table 3. These results are in 
accordance with the requested criteria of the International 
Protocol for the primary and secondary phases. Thus the 
Omron M1 Plus device fulﬁ  lls the validation criteria of the 
International Protocol.
The difference between the device readings and the 
mean BP of the device and the two observers for all 99 
points for SBP and DBP are shown in Figure 1a and Figure 
2a respectively.
Omron M6 comfort (HEM-7000-E) 
In the Omron M6 Comfort (HEM-7000-E) study, mean age 
of the 33 subjects included was 52 ± 15 (19 men and 14 
women), the arm circumference was 29 ± 4 (range: 19–34), 
so the standard cuff was used for all subjects (Table 2). The 
difference between the two observers was 0.36 ± 1.88 mmHg 
and 0.34 ± 1.14 mmHg for SBP and DBP respectively. The 
mean values of 99 measurements for SBP and DBP were 
respectively 133.8 ± 24.2/85.2 ± 13.9 mmHg with the Omron 
M6 Comfort device and 135.9 ± 22.7/85.2 ± 13.8 mmHg with 
Table 2 Age, arm circumference distribution, and BP values for all four devices populations
  Omron M1 Plus  Omron M6   Spengler KP7500D  Microlife BP A100 Plus
   Comfort 
Age (years)  58 ± 13  52 ± 15  59 ± 13  57 ± 13
Arm circ. distribution (cm)  28 ± 4  29 ± 4  30 ± 4  29 ± 4
Arm circ. range (cm)  19–38  19–34  23–40  24–38
BP (SBP/DBP) (mmHg)  136.5 ± 20.9/89.6 ± 16.4  133.8 ± 24.2/85.2 ± 13.9  138 ± 20.2/83.6 ± 17.0  141.9 ± 24.5/84.5 ± 16.4
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure.Vascular Health and Risk Management 2007:3(4) 393
Validation of automatic devices for sBPm
Table 3 Results of the OMRON M1 Plus (HEM-4011C-E) device
Phase 1     5 mmHg   10 mmHg   15 mmHg  Recomm.  
Required  One  of  25  35 40    
Achieved SBP  41  44  45  Continue   
 DBP  39  44  45  Continue   
Phase 2.1     5 mmHg   10 mmHg   15 mmHg  Recomm.  Mean diff.  SD
Required  Two  of  65  80 95    
  All  of  60  75 90    
Achieved SBP  83  97  99  Pass  –1.4  5.5
 DBP  80  93  98  Pass  –0.4  4.8
Phase 2.2    2/3   5 mmHg  0/3   5 mmHg   Recomm.  
Required    22   3      
Achieved SBP  29  0    Pass   
 DBP  27  1   Pass   
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; Recomm., recommendation; Mean diff., mean difference (mmHg); SD, standard deviation (mmHg).
the standard mercury sphygmomanometer. The mean and 
standard deviation of the difference between the device and 
the observers were –2.13 ± 7.37 and 0.09 ± 4.91 mmHg for 
SBP and DBP respectively.
In total, 45 measurements (3 measurements × 15 sub-
jects) were available for analysis in the ﬁ  rst phase of the 
validation process, and 99 (3 measurements × 33 subjects) 
in the second phase. The number of measurements differ-
ing from the mercury standard by 5, 10, and 15 mmHg or 
less are shown in Table 4. These results are in accordance 
with the requested criteria of the International Protocol 
for the primary and secondary phases. Thus the Omron 
M6 Comfort device fulﬁ  lls the validation criteria of the 
International Protocol.
The difference between the device readings and the mean 
BP of the device and the two observers for all 99 points 
for SBP and DBP are shown in Figure 1b and Figure 2b 
respectively.
Spengler KP7500D
In the Spengler KP7500D study, mean age of the 33 sub-
jects included was 59 ± 13 (21 men and 12 women), the 
arm circumference was 30 ± 4 (range: 23–40), and 29 
standard cuffs and 4 large cuffs were used (Table 2). The 
difference between the two observers was 0.01 ± 2.01 mmHg 
and 0.1 ± 1.6 mmHg for SBP and DBP respectively. The 
mean values of 99 measurements for SBP and DBP were 
respectively 138 ± 20.2/83.6 ± 17.0 mmHg with the Spengler 
KP7500D device and 139.4 ± 21.9/83.7 ± 16.3 mmHg with 
the standard mercury sphygmomanometer. The mean and 
standard deviation of the difference between the device and 
the observers were –1.4 ± 8.6 and –0.1 ± 3.5 mmHg for SBP 
and DBP respectively.
In total, 45 measurements (3 measurements × 15 subjects) 
were available for analysis in the ﬁ  rst phase of the valida-
tion process, and 99 (3 measurements × 33 subjects) in the 
second phase. The number of measurements differing from 
the mercury standard by 5, 10, and 15 mmHg or less are 
shown in Table 5. These results are in accordance with the 
requested criteria of the International Protocol for the primary 
and secondary phases. Thus the Spengler KP7500D device 
fulﬁ  lls the validation criteria of the International Protocol.
The difference between the device readings and the 
mean BP of the device and the two observers for all 99 
points for SBP and DBP are shown in Figure 1c and Figure 
2c respectively.
Microlife BP A100 plus
In the Microlife BP A100 Plus study, mean age of the 33 
subjects included was 57 ± 13 (23 men and 10 women), 
the arm circumference was 29 ± 4 (range: 24–38), and 26 
standard cuffs and 7 large cuffs were used (Table 2). The 
difference between the two observers was 0.067 ± 1.7 mmHg 
and 0.12 ± 0.98 mmHg for SBP and DBP respectively. 
The mean values of 99 measurements for SBP and DBP 
were respectively 141.9 ± 24.5/84.5 ± 16.4 mmHg with 
the Microlife BP A100 Plus device and 140.3 ± 24.7/83.9 
± 17.35 mmHg with the standard mercury sphygmoma-
nometer. The mean and standard deviation of the difference 
between the device and the observers were 1.6 ± 4.2 and 0.54 
± 2.8 mmHg for SBP and DBP respectively.
In total, 45 measurements (3 measurements × 15 subjects) 
were available for analysis in the ﬁ  rst phase of the validation 
process, and 99 (3 measurements × 33 subjects) in the second 
phase. The number of measurements differing from the mer-
cury standard by 5, 10, and 15 mmHg or less, are shown in Vascular Health and Risk Management 2007:3(4) 394
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Figure 1 Plots for systolic blood pressure (SBP) difference between the test device readings and the mean of the two observer readings in 33 participants (n = 99) 
versus the mean of the devices and the mercury sphygmomanometer readings: (a) Omron M1 Plus (HEM 4011C-E),  (b) Omron M6 Comfort (HEM-7000-E), (c) Spengler 
KP7500D, (d) Microlife BP A100 Plus.Vascular Health and Risk Management 2007:3(4) 396
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Figure 2 Plots for diastolic blood pressure (DBP) difference between the test device readings and the mean of the two observer readings in 33 participants (n = 99) 
versus the mean of the devices and the mercury sphygmomanometer readings: (a) Omron M1 Plus (HEM 4011C-E), (b) Omron M6 Comfort (HEM-7000-E), (c) Spengler 
KP7500D, (d) Microlife BP A100 Plus.Vascular Health and Risk Management 2007:3(4) 398
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Table 6. These results are in accordance with the requested 
criteria of the International Protocol for the primary and 
secondary phases. Thus the Microlife BP A100 Plus device 
fulﬁ  lls the validation criteria of the International Protocol.
The difference between the device readings and the mean 
BP of the device and the two observers for all 99 points 
for SBP and DBP are shown in Figure 1d and Figure 2d 
respectively.
Discussion
The tested devices, Omron M1 Plus (HEM-4011C-E), 
Omron M6 Comfort (HEM-7000-E), Spengler KP7500D, 
and Microlife BP A100 Plus, fulﬁ  lled the validation criteria 
of the International Protocol for SBP and for DBP. The 
International Protocol recommendations (O’Brien et al 
2002) have been published by the Working Group on Blood 
Pressure Monitoring of the ESH with the aim of simplifying 
the two main available guidelines, the BHS (O’Brien et al 
1990, 1993b) and AAMI (AAMI 1987, 1993) protocols with-
out sacriﬁ  cing their integrity. These two validation protocols 
have many similarities but experience has demonstrated that 
the conditions they recommend are sometimes extremely 
difﬁ  cult to fulﬁ  ll especially because of the large number 
of subjects who have to be recruited and the ranges of BP 
required. It has been demonstrated by the ESH Working 
Group that validation studies can be performed in such a 
way as to satisfy the criteria of the much more complicated 
earlier protocols (O’Brien et al 2002). The main advantage 
of the International Protocol is that it requires fewer subjects, 
33 instead of 85 with the two other protocols. 
Our experience with the validation of these devices shows 
that the recruitment of subjects having low SBP (90–129 
mmHg) and especially high DBP (101–130 mmHg) is the 
major factor that extends the time required for the valida-
tion, although the International Protocol recommends that 
recruitment of subjects should commence by targeting those 
Table 4 Results of the OMRON M6 Comfort (HEM 7000-E) device
Phase 1     5 mmHg   10 mmHg   15 mmHg  Recomm.  
Required One  of 25  35  40     
Achieved SBP  32  37  40  Continue   
 DBP  38  43  45 Continue   
Phase 2.1     5 mmHg   10 mmHg   15 mmHg  Recomm.  Mean diff.  SD
Required Two  of 65  80  95     
 All  of  60  75  90    
Achieved SBP  67  81  90  Pass  –2.1  7.4
 DBP  73  93  99 Pass  0.1  4.9
Phase 2.2    2/3   5 mmHg  0/3   5 mmHg   Recomm.  
Required    22   3      
Achieved SBP  25  3    Pass   
 DBP  25  3    Pass   
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; Recomm., recommendation; Mean diff., mean difference (mmHg); SD, standard deviation (mmHg).
Table 5 Results of the Spengler KP7500D device
Phase 1     5 mmHg   10 mmHg   15 mmHg  Recomm.  
Required One  of 25  35  40     
Achieved SBP  40  40  42  Continue   
 DBP  42  43  44  Continue   
Phase 2.1     5 mmHg   10 mmHg   15 mmHg  Recomm. Mean  diff.  SD
Required Two  of 65  80  95     
 All  of  60  75  90     
Achieved SBP  86  92  96  Pass  –1.4  8.6
 DBP  93  96  98  Pass  –0.1  3.5
Phase 2.2    2/3   5 mmHg  0/3   5 mmHg   Recomm.   
Required    22   3     
Achieved SBP  29  1    Pass   
 DBP  31  1   Pass   
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; Recomm., recommendation; Mean diff., mean difference (mmHg); SD, standard deviation (mmHg).Vascular Health and Risk Management 2007:3(4) 399
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likely to have pressures in the low-systolic and high-diastolic 
ranges so that it will be easy to complete the recruitment with 
the remaining ranges.
Another point that remains a limit of the present study is 
that the results are based on only one device and the valida-
tion was done in only one center; however the International 
Protocol (O’Brien et al 2002) does not specify the number 
of devices to be tested or the number of study sites recom-
mended to enhance the heterogeneity of the study population. 
The AAMI protocol (AAMI 1987, 1993) recommends more 
than one study site without specifying the number and with-
out noting the number of devices used for the validation. On 
the other hand, the BHS protocol (O’Brien et al 1990, 1993b) 
does not specify performing the validation in more than one 
site but recommends assessing the capability of a number of 
devices of the tested model to give consistent measurements. 
If substantial differences between instruments of the same 
device occur, further device validation is not appropriate. In 
this regard, Stergiou et al (2006) reported recently similar 
results for the Microlife BP A100 Plus device. 
It is important to mention here that these validation stud-
ies were performed in the general population and that the 
observed results cannot be extrapolated to speciﬁ  c popula-
tions such as the elderly, the obese, and children. Speciﬁ  c 
validation studies are needed in speciﬁ  c populations.
This study shows that increased error at extremes of BP 
occurs in virtually all non-invasive devices, but the degree of 
error varies (White et al 2001; El Assaad et al 2002; Geddes 
et al 1982). It is, however, also important to recognize that 
this usually bears little clinical relevance since therapeutic 
decisions would not signiﬁ  cantly differ (White et al 2001). 
In conclusion, the tested devices, Omron M1 Plus (HEM-
4011C-E), Omron M6 Comfort (HEM-7000-E), Spengler 
KP7500D, and Microlife BP A100 Plus have passed the 
validation criteria of the International Protocol for validation 
of BP measuring devices.
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